Management of patients with prosthetic vascular graft infection, Am Surg, vol.66, pp.166-77, 2000. ,
Vascular prosthetic graft infection: epidemiology, bacteriology, pathogenesis and treatment ,
, Acta Chir Belg, vol.102, pp.238-285, 2002.
, situ replacement of infected aortic grafts with rifampicin-bonded prostheses: the Leicester experience, vol.30, pp.92-100, 1992.
Evolution from axillofemoral to in situ prosthetic reconstruction for the treatment of aortic graft infections at a single center, J Vasc Surg, vol.43, pp.1166-74, 2006. ,
Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus ,
, J Antimicrob Chemother, vol.56, pp.996-1005, 2005.
Surgical management of infected abdominal aortic grafts: review of a 25-year experience, J Vasc Surg, vol.3, pp.725-756, 1986. ,
Diagnosis and management of aortic graft infection, Semin Vasc Surg, vol.14, pp.292-301, 2001. ,
The management of the infected aortic prosthesis: a current decade of experience, J Vasc Surg, vol.19, pp.844-50, 1994. ,
Allograft replacement for infrarenal aortic graft infection: early and late results in 179 patients, J Vasc Surg, vol.39, pp.1009-1026, 2004. ,
Contemporary management of infrarenal aortic graft infection: early and late results in 82 patients, Vascular, vol.20, pp.129-166, 2012. ,
In situ revascularization with silver-coated polyester grafts to treat aortic infection: early and midterm results, J Vasc Surg, vol.38, pp.983-992, 2003. ,
Methicillin-resistant Staphylococcus aureus infections in vascular surgery: increasing prevalence, Surg Infect, vol.5, pp.180-187, 2004. ,
Intra-abdominal aortic graft infection: prognostic factors associated with in-hospital mortality, BMC Infect Dis, vol.14, 2014. ,
Conservative treatment of vascular prosthetic graft infection is associated with high mortality, Am J Surg, vol.200, pp.47-52, 2010. ,
Diagnosis and management of prosthetic vascular graft infections, Médecine Mal Infect, vol.42, pp.102-111, 2012. ,
Long-term results of the treatment of aortic graft infection by in situ replacement with femoral popliteal vein grafts, J Vasc Surg, vol.50, pp.30-39, 2009. ,
Use of rifampin-soaked gelatin-sealed polyester grafts for in situ treatment of primary aortic and vascular prosthetic infections, J Surg Res, vol.95, pp.44-53, 2001. ,
, situ replacement of infected aortic grafts with rifampicin-bonded prostheses: the Leicester experience, 1992.
Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae, PloS One, vol.11, p.153696, 2016. ,
Carbapenem Therapy Is Associated With Improved Survival Compared With PiperacillinTazobactam for Patients With Extended-Spectrum -Lactamase Bacteremia, Clin Infect Dis, 2015. ,
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial, JAMA, vol.320, pp.984-94, 2018. ,
Medical treatment of prosthetic vascular graft infections: Review of the literature and proposals of a Working Group, Int J Antimicrob Agents, vol.46, pp.254-65, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01162387
Long-term results of cryopreserved arterial allograft reconstruction in infected prosthetic grafts and mycotic aneurysms of the abdominal aorta, J Vasc Surg, vol.34, pp.616-638, 2001. ,
Management of infected grafts and mycotic aneurysms of the aorta using cryopreserved homografts, Cardiovasc Surg Lond Engl, vol.11, pp.257-63, 2003. ,
A prospective audit of complex wound and graft infections in Great Britain and Ireland: the emergence of MRSA, Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg, vol.21, pp.289-94, 2001. ,
Risk factors for methicillin-resistant staphylococcal vascular graft infection in an 11-year cohort study, J Infect, vol.64, pp.441-445, 2012. ,
Impact of the use of aminoglycosides in combination antibiotic therapy on septic shock and mortality due to Staphylococcus aureus bacteremia, Eur J Intern Med, vol.17, pp.276-80, 2006. ,
Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials, BMJ, vol.328, p.668, 2004. ,
Endovascular stent-graft repair of failed endovascular abdominal aortic aneurysm repair, Ann Vasc Surg, vol.22, pp.30-36, 2008. ,
Evolution from axillofemoral to in situ prosthetic reconstruction for the treatment of aortic graft infections at a single center, J Vasc Surg, vol.43, pp.1166-74, 2006. ,
Early and Late Results of Contemporary Management of 37 Secondary Aortoenteric Fistulae, Eur J Vasc Endovasc Surg, vol.41, pp.748-57, 2011. ,
Comparison of Genus Specific PCR and Culture with or without Sonication for Microbiological Diagnosis of Vascular Graft Infection, Eur J Vasc Endovasc Surg, 2018. ,
The use of tubes constructed from vinyon "N" cloth in bridging arterial defects, Ann Surg, vol.135, pp.332-338, 1952. ,
, Commission Nationale d'évaluation des dispositifs medicaux et des technologies de santé, 2013.
, Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators
, Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome, JAMA, vol.302, pp.1888-95, 2009.
Nonvalvular cardiovascular device-related infections, Circulation, vol.108, pp.2015-2046, 2003. ,
Nonvalvular cardiovascular device-related infections, Circulation, vol.108, pp.2015-2046, 2003. ,
Vascular prosthetic graft infection: epidemiology, bacteriology, pathogenesis and treatment ,
, Acta Chir Belg, vol.102, pp.238-285, 2002.
Characteristics and prognosis in patients with prosthetic vascular graft infection: a prospective observational cohort study, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.18, pp.352-360, 2012. ,
Contemporary management of infrarenal aortic graft infection: early and late results in 82 patients, Vascular, vol.20, pp.129-166, 2012. ,
Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus ,
, J Antimicrob Chemother, vol.56, pp.996-1005, 2005.
Extracorporeal life support for respiratory failure after multiple trauma, J Trauma, vol.37, pp.266-72, 1994. ,
The management of endograft infections following endovascular thoracic and abdominal aneurysm repair, J Vasc Surg, vol.58, pp.1179-85, 2013. ,
A systematic review and meta-analysis of treatments for aortic graft infection, J Vasc Surg, vol.44, pp.38-45, 2006. ,
In situ rifampin-soaked grafts with omental coverage and antibiotic suppression are durable with low reinfection rates in patients with aortic graft enteric erosion or fistula, J Vasc Surg, vol.53, pp.106-107, 2011. ,
Evaluation of the anti-infectious properties of polyester vascular prostheses functionalised with cyclodextrin, J Infect, vol.68, pp.116-140, 2014. ,
Prosthetic vascular graft infection: A risk factor analysis using a case-control study ,
, J Infect, vol.53, pp.49-55, 2006.
Medical treatment of prosthetic vascular graft infections: Review of the literature and proposals of a Working Group, Int J Antimicrob Agents, vol.46, pp.254-65, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01162387
The impact of MRSA on vascular surgery, Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg, vol.22, pp.211-215, 2001. ,
A prospective audit of complex wound and graft infections in Great Britain and Ireland: the emergence of MRSA, Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg, vol.21, pp.289-94, 2001. ,
Nosocomial MRSA infection in vascular surgery patients: impact on patient outcome, Vasc Endovascular Surg, vol.39, pp.327-361, 2005. ,
Risk factors for methicillin-resistant staphylococcal vascular graft infection in an 11-year cohort study, J Infect, vol.64, pp.441-445, 2012. ,
Hemodialysis graft infections treated with cryopreserved femoral vein, Cardiovasc Surg Lond Engl, vol.10, pp.561-566, 2002. ,
Redo aortic grafting after treatment of aortic graft infection, J Vasc Surg, vol.24, pp.336-337, 1996. ,
Alternative approach for management of infected aortic grafts, J Vasc Surg, vol.25, pp.106-118, 1997. ,
Diagnosis and management of prosthetic vascular graft infections, Médecine Mal Infect, vol.42, pp.102-111, 2012. ,
Aortic and peripheral prosthetic graft infection: differential management and causes of mortality, Am J Surg, vol.150, pp.36-43, 1985. ,
Early and Late Results of Contemporary Management of 37 Secondary Aortoenteric Fistulae, Eur J Vasc Endovasc Surg, vol.41, pp.748-57, 2011. ,
Allograft replacement for infrarenal aortic graft infection: early and late results in 179 patients, J Vasc Surg, vol.39, pp.1009-1026, 2004. ,
Long-term results of cryopreserved arterial allograft reconstruction in infected prosthetic grafts and mycotic aneurysms of the abdominal aorta, J Vasc Surg, vol.34, pp.616-638, 2001. ,
Conservative treatment of vascular prosthetic graft infection is associated with high mortality, Am J Surg, vol.200, pp.47-52, 2010. ,
Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum ?-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis, J Antimicrob Chemother, vol.67, pp.1311-1331, 2012. ,
Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact, Curr Opin Infect Dis, vol.23, pp.320-326, 2010. ,
, L'evolution des consommations d'antibiotiques en France entre, Janvier 2017 ANSM, 2000.
Global spread of Carbapenemase-producing Enterobacteriaceae, Emerg Infect Dis, vol.17, pp.1791-1799, 2011. ,
Vascular graft infections in the intensive care unit: Clinical spectrum and prognostic factors, J Infect, vol.62, pp.204-215, 2011. ,
, Surveillance des infections nosocomiales en réanimation adulte / 2018 / Maladies infectieuses / Rapports et synthèses / Publications et outils / Accueil n.d, 2018.
Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative Staphylococci isolated from orthopedic-device-associated infections, J Clin Microbiol, vol.48, pp.1428-1459, 2010. ,
Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.29, pp.1171-1178, 1999. ,
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.46, pp.193-200, 2008. ,
Relationship between vancomycin MIC and failure among patients with methicillinresistant Staphylococcus aureus bacteremia treated with vancomycin, Antimicrob Agents Chemother, vol.52, pp.3315-3335, 2008. ,
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity, Arch Intern Med, vol.166, pp.2138-2182, 2006. ,
Clinical management of Staphylococcus aureus bacteremia: a review, JAMA, vol.312, pp.1330-1371, 2014. ,
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, N Engl J Med, vol.355, pp.653-65, 2006. ,
Factors predictive of treatment failure in staphylococcal prosthetic vascular graft infections: a prospective observational cohort study: impact of rifampin, BMC Infect Dis, vol.14, 2014. ,
, Statistiques de résistance dans des infections documentées et dans des contexte épidémiologiques
Surveillance en incidence / Surveillance des infections associées aux soins (IAS) / Infections associées aux soins / Maladies infectieuses / Dossiers thématiques, 2018. ,
Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae, Lancet Lond Engl, vol.2, pp.302-308, 1987. ,
Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype, Diagn Microbiol Infect Dis, vol.57, pp.341-345, 2007. ,
Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli, Diagn Microbiol Infect Dis, vol.56, pp.313-318, 2006. ,
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study, Antimicrob Agents Chemother, vol.47, pp.3442-3449, 2003. ,
Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum betalactamase-producing Enterobacteriaceae: MIC matters, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.56, pp.488-95, 2013. ,
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum ?-lactamases: a systematic review and meta-analysis, J Antimicrob Chemother, vol.67, pp.2793-803, 2012. ,
Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae, PloS One, vol.11, p.153696, 2016. ,
Carbapenem Therapy Is Associated With Improved Survival Compared With PiperacillinTazobactam for Patients With Extended-Spectrum -Lactamase Bacteremia, Clin Infect Dis, 2015. ,
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial, JAMA, vol.320, pp.984-94, 2018. ,
Impact of the use of aminoglycosides in combination antibiotic therapy on septic shock and mortality due to Staphylococcus aureus bacteremia, Eur J Intern Med, vol.17, pp.276-80, 2006. ,
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.62, pp.1-50, 2016. ,
The results of in situ prosthetic replacement for infected aortic grafts, Am J Surg, vol.178, pp.136-176, 1999. ,
Microbial spectrum and primary resistance to rifampicin in infectious complications in vascular surgery: limits to the use of rifampicin-bonded prosthetic grafts, Angiology, vol.61, pp.423-429, 2010. ,
,
, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité
, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux
, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte
, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité?deshérité?des circonstances pour forcer les consciences. Je donnerai mes soins à l'indigent et à quiconque me les demandera, J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences
, Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs. Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies
, Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés. J'apporterai mon aide à mes confrères ainsi qu
, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses
, , vol.10, 2018.
,
,
, Vous nous avez sollicite?ssollicite?s a? propos d'un projet intitule?:intitule?: Réévaluation du protocole antiinfectieux probabiliste au cours de la prise en charge des infections de prothèses vasculaires aortiques
ne soule? ve pas de proble? me e?thiquee?thique particulier et ne rele? ve pas du domaine d'application de la re?glementationre?glementation re?gissantre?gissant les recherches impliquant la personne humaine, au sens de l'Article L.1121-1-1 et l'Article R, pp.1121-1124 ,
, Nous attirons neánmoins votre attention sur le fait que, dans ce contexte, du fait de l'enregistrement des diffe?rentesdiffe?rentes donneés et informations, il vous appartient de vous renseigner sur les obligations lieés aux de?clarationsde?clarations aupre? s de la CNIL Veuillez agréer, Monsieur, l'expression de nos salutations distinguées
, If not previously started, an antimicrobial therapy must be started intra-operatively but there is not consensus about the ideal empirical treatment. The aim of this study was to analyze and report the bacterial epidemiology and prognosis of AGI in the intensive care unit (ICU) in order to reassess this empirical therapy, Le Responsable du Comite?dComite?d'éthique pour la recherche en Anesthe?sieAnesthe?sie-Reánimation Pr. JE. BAZIN SFAR - 74 rue Raynouard 75016 Paris www.sfar.org contact : cerar@sfar.org ABSTRACT Background, 2008.
, Echinocandin was added if aorto-enteric fistula (AEF) was suspected. Primary outcome was the appropriateness of antibiotherapy. Thirty-day and in-hospital mortality were defined as secondary outcome. Results: During the study period
, Using a combination of carbapenem with anti MRSA as initial empirical treatment, we would achieve 99% coverage with the first line treatment. Thirty-day mortality rate was 24% and in hospital mortality rate was 37%. Conclusion: Aortic graft infection carries high morbidity and mortality rates. We recommend the use of carbapenem with anti-MRSA as first line antibiotherapy in AGI, Gram positive cocci (GPC) were the most commonly implicated (n=104), with streptococci (n=39)